Abstract: Provided are establishment and suspension acclimation of a Crandell Reese Feline Kidney (CRFK) adherent cell line, and its application. The CRFK cell line, named CRFK-BLA, is deposited at the China General Microbiological Culture Collection Center (CGMCC), with the address being Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, the deposit number being CGMCC NO: 45703; the CRFK cell line was classified and named CRFK cells, and was deposited on Aug. 17, 2023. A serum-free complete suspension culture type CRFK cell line obtained by acclimation on the basis of CRFK-BLA is named CRFK-BLS, and is deposited at the China General Microbiological Culture Collection Center (CGMCC), with the address being Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, the deposit number being CGMCC NO: 45704; the CRFK cell line was classified and named CRFK suspension cells.

Abstract: Provided is an oncolytic virus expressing a PD-1 binding protein, i.e., an oncolytic adenovirus comprising a fusion protein expressing a PD-1 single-chain antibody, wherein the fusion protein has a structure of S-VL-L-VH-Fc, S is an optional signal peptide sequence, VL is the light chain variable region of the PD-1 single-chain antibody, L is a flexible linker, VH is the heavy chain variable region of the PD-1 single-chain antibody and Fc is an immunoglobulin Fc fragment.

Abstract: A virus lysis and nucleic acid preservation solution is disclosed, including the following components: isopropanol or ethyl alcohol, guanidinium chloride, tri (hydroxymethyl) aminomethane hydrochloride, and ethylenediaminetetraacetic acid. Furthermore, a kit including the virus lysis and nucleic acid preservation solution, a method for preserving viral nucleic acid, and a method for extracting a viral nucleic acid are also provided. The virus lysis and nucleic acid preservation solution of the present invention has the functions of lysing virus and preserving nucleic acid in the lysed virus samples, and it is compatible with lysis buffers, wash buffers, elution buffers, etc. in all kinds of viral nucleic acid extraction kit commonly available in the market.

Abstract: Generation of monoclonal antibodies, or fragments thereof, that recognize the human parainfluenza virus (human PIV) chimeric protein L, where the monoclonal antibodies or fragments thereof have a heavy chain variable region and a light chain variable region. In addition, a method of diagnosing human PIV infection in a biological sample of nasopharyngeal secretion is provided, using the monoclonal antibodies in diagnostic kit format.

Abstract: Generation of monoclonal antibodies, or fragments thereof, that recognize the PB2 protein of the human influenza A virus (Flu), where the monoclonal antibodies or fragments thereof, has a heavy chain variable region and light chain variable region. Furthermore, a diagnostic method is provided to detect Flu infections in biological samples of nasopharyngeal secretions, using monoclonal antibodies in diagnostic kit format.

Abstract: Disclosed is a replication-defective Ad35-vectored immunogenic composition for inducing immune response against SARS COV-2, comprising an Ad35 vector, wherein the Ad35 vector encodes the optimized nucleic acid sequence of SEQ ID NO: 1. Some embodiments of the present disclosure have better safety and use convenience. Experiments have shown that the immunogenic composition can produce more S proteins in human cells. Some embodiments of the present disclosure may be used in combination with another immunogenic composition or may also be used as a therapeutic immunogenic composition for Corona Virus Disease 2019. When a patient is immunized with the Ad35-vectored immunogenic composition of the present disclosure at the initial stage of infection, the immunogenic composition induces an immune response in the human body, thereby achieving a therapeutic effect.

Abstract: The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.